Department of Ophthalmology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland; Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland; Department of Molecular Genetics, University of Lodz, Lodz, Poland.
Centre for Experimental Medicine, The Wellcome-Wolfson Institute of Experimental Medicine, Queen's University Belfast, Belfast, UK; Aier School of Ophthalmology, Central South University, China.
Adv Drug Deliv Rev. 2018 Feb 15;126:177-184. doi: 10.1016/j.addr.2018.04.016. Epub 2018 Apr 23.
The retina is constantly exposed to light that increases reactive oxygen species in retina. Oxidative stress, inflammation and neurodegeneration are the major contributors in the most common retinal diseases, such as age-related macular degeneration (AMD), glaucoma and diabetic retinopathy (DR). Emerging developments and research for novel therapy targets and drug delivery to the posterior segment offer a promising future for the treatment of retinal diseases including rare hereditary diseases. In this review we discuss about promising mechanistical retinal drug targets. Vascular endothelial growth factor (VEGF) signaling and anti-VEGF treatments are excluded.
视网膜不断受到光线的刺激，导致视网膜中活性氧的增加。氧化应激、炎症和神经退行性变是最常见的视网膜疾病（如年龄相关性黄斑变性（AMD）、青光眼和糖尿病性视网膜病变（DR））的主要诱因。针对新型治疗靶点的新兴发展和研究以及向眼后段的药物输送为包括罕见遗传性疾病在内的视网膜疾病的治疗提供了广阔的前景。在这篇综述中，我们讨论了有前途的视网膜药物靶点的机制。血管内皮生长因子（VEGF）信号和抗 VEGF 治疗除外。
